☆ 4.6 Letter

Universal Genetic Testing to Identify Pathogenic Germline Variants in Patients With Cancer COMMENT

JAMA ONCOLOGY (2021)

Related references

Note: Only part of the references are listed.
Article Oncology

Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome

N. Jewel Samadder et al.

Summary: This cohort study found that universal multigene panel testing among patients with solid tumor cancer was associated with an increased detection of heritable variants over the predicted yield of targeted testing based on guidelines. Nearly 30% of patients with high-penetrance variants had modifications in their treatment based on the finding. The uptake of cascade FVT was low despite being offered at no cost.

JAMA ONCOLOGY (2021)

Add to Collection
Review Genetics & Heredity

MUTYH-associated polyposis: Review and update of the French recommendations established in 2012 under the auspices of the National Cancer institute (INCa)

Chrystelle Colas et al.

EUROPEAN JOURNAL OF MEDICAL GENETICS (2020)

Add to Collection
Article Oncology

Decoding hereditary breast cancer benefits and questions from multigene panel testing

Chrystelle Colas et al.

BREAST (2019)

Add to Collection
Article Oncology

Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion

Elena M. Stoffel et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection
Review Oncology

Evaluation of the methods to identify patients who may benefit from PARP inhibitor use

Diana Lim et al.

ENDOCRINE-RELATED CANCER (2016)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.